# TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)

> **NCT00960518** · PHASE2 · UNKNOWN · sponsor: **Tongji University** · enrollment: 216 (estimated)

## Conditions studied

- Hepatitis B Virus
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** adefovir
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT00960518
- **Lead sponsor:** Tongji University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-08
- **Primary completion:** 2012-08
- **Final completion:** 2015-08
- **Target enrollment:** 216 (ESTIMATED)
- **Last updated:** 2009-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00960518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00960518, "TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00960518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*